Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats

References

• Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int. 2009;76(1):23–31.
   PubMed Web of Science ®Google Scholar
• Epstein BJ, Smith SM, Choksi R. Recent changes in the landscape of combination RAS blockade. Expert Rev Cardiovasc Ther. 2009;7(11):1373–84.
   PubMedGoogle Scholar
• Düsing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin. 2009;25(9):2287–301.
   PubMed Web of Science ®Google Scholar
• Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, Markovic M, Barbosa-Sicard E, Dechend R, Wellner M, et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol. 2004;164:521–32.
   PubMed Web of Science ®Google Scholar
• Carey RM. Antihypertensive and renoprotective mechanisms of renin inhibition in diabetic rats. Hypertension. 2008;52:63–64.
   PubMed Web of Science ®Google Scholar
• Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52(1):130–36.
   PubMed Web of Science ®Google Scholar
• Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)rennin receptor. Curr Opin Pharmacol. 2008;8(2):127–32.
   PubMed Web of Science ®Google Scholar
• Kanematsu Y, Yamaguchi K, Ohnishi H, Motobayashi Y, Ishizawa K, Izawa Y, Kawazoe K, Kondo S, Kagami S, Tomita S, et al. Dietary doses of nitrite restore circulating nitric oxide level and improve renal injury in L-NAME-induced hypertensive rats. Am J Physiol Renal Physiol. 2008;295(5):F1457–1462.
   PubMed Web of Science ®Google Scholar
• Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23(2):417–26.
   PubMed Web of Science ®Google Scholar
• Müller DN, Derer W, Dechend R. Aliskiren—mode of action and preclinical data. J Mol Med. 2008;86:659–6621.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the eolin phenol reagent. St. Louis (MI): Department of Pharmacology, Washington University School oj Medicine; 1951. Received for publication, May 28, 1951.
   Google Scholar
• Gutmann I, Bergmeyer HU, Dans Bergmeyer HU. Methoden der enzymatischen analyse. 3rd ed. Wheinheim: tome Verlag chemie; 1974. p. 1842.
   Google Scholar
• Wahlefeld AW, Holz G, Dans Bergmeyer HU, Bergmeyer HU. Methoden der enzymatischen analyse. 3rd ed. Wheinheim: tome Verlag chemie; 1974. p. 1834–38.
   Google Scholar
• Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–10.
   PubMedGoogle Scholar
• Marklund SL. Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. J Biol Chem. 1992;267:6696–701.
   PubMed Web of Science ®Google Scholar
• Ribeiro MO, Antunes E, Muscará MN, De Nucci G, Zatz R. Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension. 1995;26:150–55.
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, Takeshita A. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens. 2000;18(12):1795–800.
   PubMed Web of Science ®Google Scholar
• Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569–76.
   PubMed Web of Science ®Google Scholar
• Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009;54(3):633–38.
   PubMed Web of Science ®Google Scholar
• Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708–14.
   PubMed Web of Science ®Google Scholar
• Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int. 2007;72:45–52.
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, Johnson MS, Tilmon R, Rehmer N, Ferrario CM, Sowers JR. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol. 2010;298(3):F655–661.
   PubMed Web of Science ®Google Scholar
• Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem. 1993;268:11617–21.
   PubMed Web of Science ®Google Scholar
• Poulsen K, Jacobsen S. Enzymatic reactions of the renin-angiotensin system. In: Robertson JIS, Nicholls MG, editors. The Renin-Angiotensin System. London (UK): Mosby; 1993.
   Google Scholar
• Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. Rev Sci World J. 2009;9:522–35.
   Google Scholar
• Nakamura Y, Ono H, Zhou X, Frohlich ED. Angiotensin type 1 receptor antagonism and ace inhibition produce similar renoprotection in n-nitro-l-arginine methyl ester/spontaneously hypertensive rats. Hypertension. 2001;37:1262–67.
   PubMed Web of Science ®Google Scholar